India's exporters have spent 2026 navigating one of the most unpredictable trade policy environments in living memory. The United States, which is India's largest export destination, has lurched through sweeping tariff announcements, Supreme Court rulings striking them down, alternative tariff mechanisms, new bilateral deals, and sector-specific duties — all within five months. Understanding where India's exports stand amid this turbulence matters for every company that sells goods or services to the American market, and for investors who own their stocks.
The most important number for Indian exporters: the India-US bilateral trade deal signed on February 2, 2026, caps US tariffs on Indian goods at 18%. Below the chaotic headline tariff announcements, India has secured a framework that limits the worst-case outcome.
What Happened
The tariff turmoil began in early 2026 when President Trump invoked emergency powers to impose sweeping global tariffs on imports from virtually all trading partners. The legal basis was challenged immediately.
February 20, 2026: The US Supreme Court struck down Trump's sweeping global tariffs, ruling the president had overstepped executive authority by using emergency powers for what was fundamentally a trade policy decision requiring Congressional authorisation. This was a significant constitutional check on executive trade action.
February 24, 2026: Trump invoked Section 122 of the Trade Act of 1974, imposing a 15% universal global tariff. Section 122 allows a temporary tariff during a balance of payments emergency, which Trump's team argued applied given the US trade deficit.
May 7, 2026: The Court of International Trade declared the Section 122 tariffs invalid, finding that the balance of payments justification was not substantiated. The administration began exploring other legal mechanisms, and the tariff situation entered another period of uncertainty.
Critically, between these court battles, India had already secured its position. On February 2, 2026, one day before the broader tariff chaos escalated, India and the US announced a bilateral trade agreement setting US tariffs on Indian goods at 18%. This framework, while not covering every product category, provides a negotiated baseline that is far better than the 50%+ combined tariff rates that had been threatened when the US factored in the India-specific surcharge related to India's purchase of Russian oil.
The pharma tariff is the sector-specific threat that remains active. The US separately announced that it would impose 100% tariffs on imported patented pharmaceutical drugs, with implementation dates of July 31, 2026 for companies named in the order and September 29, 2026 for others. This is not part of the broader tariff litigation and has its own legal pathway.
Why This Matters for Investors
India's merchandise exports to the US totalled approximately $77 billion in FY25, making the US the single largest export market. The tariff environment directly affects the earnings of India's export-oriented companies and, by extension, their stock performance.
Pharmaceutical sector: India's pharma exports to the US were $9.7 billion in FY25, the largest US-export category for the sector. India is the largest supplier of generic drugs to the US, covering approximately 47% of all generic prescriptions. The 100% tariff on patented drugs from July 2026 primarily affects innovator drugs, not generics, which limits the direct impact on India's generics-focused pharma industry. However, some Indian pharmaceutical companies have growing specialty drug and patented product pipelines in the US market that could be affected. Sun Pharma, Dr Reddy's, Cipla, and Aurobindo Pharma are the companies most scrutinised for US exposure.
IT services: TCS, Infosys, Wipro, HCL Tech, and others export services, not goods. They are not directly subject to goods tariffs. The indirect risk is that tariff-induced US economic slowdown reduces tech spending. At the current tariff uncertainty level, analysts estimate 2 to 3% FY27 IT revenue growth impact per 0.5% US GDP slowdown.
Gems and jewellery: India's $8 billion-plus gems and jewellery exports to the US face the 18% bilateral deal rate, which, while impactful, is manageable compared to the 50%+ previously threatened. Companies like Titan benefit from a stable bilateral framework.
Textiles: Under the bilateral deal, Indian textiles face a competitive environment where competitors (Vietnam, Bangladesh) are facing their own tariff issues with the US, potentially levelling the playing field.
Market Reaction
Indian export-oriented sectors saw significant volatility through February to May 2026 as the tariff headlines whipsawed. Pharma stocks, in particular, have faced selling pressure from the 100% drug tariff risk despite the limited direct impact on generics.
The India-US bilateral deal at 18% was received positively, as it provided a floor below the worst-case scenarios that had been discussed. The specific India-US deal rate of 18% is broadly in line with what analysts had modelled as an acceptable outcome and does not significantly undermine the competitiveness of most Indian export categories.
The ongoing US tariff litigation uncertainty, however, means that companies with large US goods export exposure have struggled to provide definitive guidance to investors. Several management teams have noted the difficulty of planning with precision until the US tariff legal landscape stabilises.
What Investors Should Watch
The July 31 pharma tariff implementation date is the most concrete near-term event. Watch whether Indian pharma companies file for the US onshoring commitment to qualify for the reduced 20% rate (versus the 100% default). Companies like Sun Pharma, Dr Reddy's, and Cipla that have US manufacturing investments or expansion plans may be better positioned to qualify.
US tariff litigation resolution is the background watch item. The Trump administration's search for an alternative legal mechanism for broad tariffs could produce new announcements. Any new tariff framework that covers services or digital goods would be a direct risk for India's IT sector.
India-US trade deal second-phase negotiations may cover services and digital trade. If a comprehensive trade agreement is signed, it could lock in favourable terms for India's IT services sector and further reduce tariff risk for goods exporters.
Risks to Monitor
The July 31 pharma tariff, even if limited in direct impact today, sets a precedent for US trade policy targeting specific sectors. If the 100% drug tariff is extended to generic drugs or medical devices in a subsequent executive order, the impact on India's pharma industry becomes severe. The RBI and Ministry of Commerce are monitoring this trajectory.
Trade diversion from India to other exporters is a risk if Indian goods tariffs at 18% are higher than tariffs on competing countries that negotiated better deals. Vietnam, Indonesia, and other Asian exporters are in simultaneous negotiations with the US, and their tariff outcomes relative to India will affect India's export competitiveness.
The broader US-China trade war creates both risk and opportunity for India. If US-China tariffs remain high, Indian manufacturers that can substitute Chinese products for the US market stand to benefit. Electronics components, solar panels, and specialty chemicals are categories where India can capture Chinese supply displacement. But if US-China tariffs are resolved through a deal, that displacement opportunity shrinks.
India's export story in 2026 is one of resilience through turbulence. The bilateral trade deal at 18% protects the bulk of merchandise exports. The pharma tariff threat is real but concentrated. The IT sector remains insulated from direct tariff risk. The biggest uncertainty is whether the US tariff legal chaos stabilises into a predictable regime, or continues generating volatility that makes export planning impossible.